Haegarda (C1 esterase inhibitor) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGH	HT (LB/KG): ALLERGIES:			

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page



Haegarda (C1 esterase inhibitor) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	R MEDICATIONS FOR THIS CONDITION? DURATION OF THERAPY (SPECIFY DATES):	YES (if yes, complete below) NO RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
 Hereditary Angioedema (HAE) Other diagnosis:ICD-10 				
3. REQUIRED CLINICAL INFORMATION: PRIOR AUTHORIZATION.	PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
Clinical Information: Is this drug being prescribed to this patient as part of a treatment regimen specified within a sponsored clinical trial? Has patient had four or more hereditary angioedema attacks over a 2-month consecutive period that required acute treatment, medical attention or caused significant functional impairment? Yes No				
Is patient's functional C1-inhibitor level less than 50%? Yes No (Copy of lab report must be submitted.)				
Is patient's C4 antigen level below the laboratory's listed reference range? Yes D No (Copy of lab report must be submitted.)				
Has patient had an inadequate respon	se with attenuated androgens(such as o	danazol)? 🗆 Yes 🗆 No		
 Does patient have at least one (1) contraindication to the use of attenuated androgens (such as danazol)? Yes No Please select one: Hypersensitivity to the androgen or any component of the formulation Undiagnosed genital bleeding Pregnancy Breastfeeding Porphyria Impaired hepatic function Impaired renal function Impaired cardiac function 				
Is patient going to be using any other HAE prophylactic agent such as Takhzyro (lanadelumab-flyo), Cinryze (C1 esterase inhibitor), or Orladeyo (berotralstat) in combination with Haegarda? _ Yes _ No				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				



Haegarda (C1 esterase inhibitor) **Prior Authorization Request Form Caterpillar Prescription Drug Benefit**

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: ______ MEMBER'S FIRST NAME: _____

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP - 4201

P.O. Box 64811

St. Paul, MN 55164-0811

